We are monitoring the impact of COVID-19 on Therapeutic Vaccines Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 54
Share on
Share on

Global Therapeutic Vaccines Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Disease Type & Region - Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 54
Pages: 177

Therapeutic Vaccines Market Size (2021 to 2026)

The size of the global therapeutic vaccines market is predicted to be worth USD 15356 million by 2026 from USD 3607 million in 2021, growing at a CAGR of 33.6% from 2021 to 2026. Several approaches are being developed in the pipeline to boost the immune response to various infectious and cancerous cells.

The therapeutic vaccines market is different from any other product market. Compared to the pharmaceutical market, it is relatively small, although growing at a fast rate. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years. The vaccine market is relatively concentrated on both the supply and demand sides. It is highly regulated and mostly dependent on public purchasers and donor policies. It has very distinct features that increase the complexity of assessing and understanding pricing and procurement in their context.

MARKET DRIVERS:

Increased government funding for vaccine development, increased investments by major market players, increasing disease prevalence, technological advances, and NGOs' initiatives are some of the factors driving the global therapeutic vaccines market forward.

Due to the increasing incidence of diseases like cancer and HIV, therapeutic vaccines have become more popular. Some of the key factors driving the growth of the global therapeutic vaccines market are technological advances in HIV diagnosis and increased clinical trials for HIV and cancer vaccines. Furthermore, rising public awareness of serious diseases and increased R&D investments in therapeutic vaccines boost the therapeutic vaccines market growth.

An increase in funding’s from the government for vaccine development, a rise in investments by the major market players, rising prevalence of the disease, technological advancements, initiatives by NGOs are some of the factors that are propelling the market growth.

The significant increase in the prevalence of various chronic diseases, such as cancer, HIV, and cardiovascular diseases, has significantly impacted the global market for therapeutic vaccines. The alarming rise in the demand for effective treatment has shifted global attention to therapeutic vaccines. Several pharmaceutical companies have begun developing novel vaccines for breast cancer, lung cancer, and Alzheimer's disease. Even though these innovations are still in the pipeline and have yet to be commercialized, they point to a new opportunity for the global therapeutic vaccine market. In addition, human papillomavirus-mediated cancers will present a growth opportunity for the global therapeutic vaccines market.

MARKET RESTRAINTS:

However, massive capital expenditures and stringent regulatory policies, and high costs associated with treatment are few factors inhibiting the market's growth. The global therapeutic vaccines market is restricted by higher vaccine costs and a lack of therapeutic drug availability. Furthermore, the global therapeutic vaccines market is hampered by strict regulatory requirements for therapeutic vaccine approval. The market is being limited by inefficient research and development and reimbursement policies. However, the vaccine can treat a wide range of chronic diseases; these constraints will weaken over time.

Adverse side effects of therapeutic vaccination and lack of awareness may threaten the global therapeutic vaccines market's expansion. Market growth will be hampered by issues such as the high cost of developing therapeutic vaccines. There is, however, one challenge in this situation. Vaccine R&D takes a long time and requires a lot of money, just like drug development. Clinical trials must be completed before a vaccine can be released commercially. The majority of vaccines are rejected at each stage of the clinical trial. By the time the final product is approved for commercial use, a significant amount of money has been spent on the vaccine development R&D process. These are the challenges faced by the market.

Impact of Covid-19 on the global therapeutic vaccines market:

As the COVID-19 virus spreads around the world, countries and medical regulators will speed up vaccine development. Due to the impact of the COVID-19 pandemic in the first half of 2020, the global therapeutic vaccines market is expected to expand by USD 3.78 billion, a substantial increase over 2019 growth estimates. A therapeutic vaccine is a combination of biologics used to develop immunity against abnormal cells in the body. Therapeutic vaccines can be customized to the patient's needs and used to treat a variety of disorders and diseases, including cancer, HIV infection, and Alzheimer's disease. New vaccines that target various types of cancers are growing rapidly amid the focus on COVID vaccines. Therapeutic vaccines aid in the treatment of diseases by inducing or strengthening the immune response. However, the therapeutic vaccine market has been held back by a small number of well-established therapeutic vaccines with well-studied properties. Various studies and demand for biologics have resulted in a major shift in the growth graph toward high value. As a result, the Therapeutic vaccine market has had positive growth during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Disease Type and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Market Leaders Profiled

GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

 

This research report on the global therapeutic vaccines market has been segmented and sub-segmented based on the disease type and region.

Therapeutic Vaccines Market - By Disease Type:

  • Autoimmune Disease Vaccines      
  • Cancer Vaccines   
    • Multikine
    • PR1 Peptide
    • Truax
    • CYT004-MelQbG10
  • Neurological Disease Vaccines        
    • ACC- 001
    • CAD 106
    • Parkinson's Vaccine
    • Alzheimer's Vaccine
  • Infectious Disease Vaccines             
    • Hepatitis C Vaccines
    • HIV/AIDS Vaccines
    • Other Infectious Disease Vaccines

Based on the disease type, autoimmune disease vaccines are holding dominant shares of the market. Increasing prevalence for the manufacturing of various vaccines for different diseases to promote significant results primarily accelerates the demand for the market. People's interest in innovative developments with the latest technologies is significantly influencing the demand of the market. The rise in the need for targeted diseases is also surging the growth of the market. Therapeutic vaccines are highly effective in treating the disease with fewer or no side effects, which are also ascribed to bolster the market's growth rate. The market is also to grow with the increasing support from the private and public organizations on healthcare centers.

Therapeutic Vaccines Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

North America is witnessed in leading dominant market shares, with the rise in patients' flow suffering from chronic diseases. Acceptance of advanced technology and the launch of new products in favor of the end-users are likely to outshine the demand of the therapeutic vaccines market in this region. Growing awareness over the availability of different therapies among individuals is escalating the growth of the market. Stringent rules and regulations by the government are also an attribute lavishing the development of the market. The U.S.A is the major country contributing to the highest shares for the market in North America. The increased production rate of the vaccines and the growing development of new vaccines in research centers are significant factors for the market growth in the USA. Europe is positioned next to North America in leading prominent shares of the market. An increase in the deaths of women and children due to autoimmune disease is solely to leverage the market demand. The rising scale of healthcare centers with new techniques for chronic and fatal diseases is accelerating the market demand in this region.

Asia Pacific has had a tremendous growth rate from the past decade and hit the highest CAGR in the near future. The rise in the geriatric population and growing concern towards health is elevating the growth of the market. Also, increasing disposable income in urban areas is spurring the growth rate of the therapeutic vaccines market.

KEY MARKET PLAYERS:

Some of the prominent companies influencing the global preventive vaccine market are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.

Multinational vaccine companies have historically conducted much of the innovation, research, and development in vaccine production. They have used significant revenues, global size, and more profound expertise to fund.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Analysis Design                         

                2.3 Research Phases                      

                                2.3.1 Secondary Research            

                                2.3.2 Primary Research 

                                2.3.3 Econometric Modelling     

                                2.3.4 Expert Validation  

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Disease Type                       

                                5.1.1 Autoimmune Disease Vaccines      

                                5.1.2 Cancer Vaccines   

                                                5.1.2.1 Multikine

                                                5.1.2.2 PR1 Peptide

                                                5.1.2.3 TroVax

                                                5.1.2.4 CYT004-MelQbG10

                                5.1.3 Neurological Disease Vaccines        

                                                5.1.3.1 ACC- 001

                                                5.1.3.2 CAD 106

                                                5.1.3.3 Parkinson's Vaccine

                                                5.1.3.4 Alzheimer's Vaccine

                                5.1.4 Infectious Disease Vaccines             

                                                5.1.4.1 Hepatitis C Vaccines

                                                5.1.4.2 HIV/AIDS Vaccines

                                                5.1.4.3 Other Infectious Disease Vaccines

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 South Korea           

                6.4 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Argentina

                                6.4.4 Mexico     

                6.5 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle East            

                                6.5.3 Africa        

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 GlaxoSMithKline plc.                              

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues            

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 Merck and Company                              

                8.3 Bavarian Nordic                        

                8.4 CSL Limited                 

                8.5 Emergent Biosolutions Inc.                  

                8.6 Novartis AG                

                8.7 Johnson and Johnson                             

                8.8 MedImmune LLC                     

                8.9 Pfizer Inc.                    

                8.10 Sanofi Pasteur                        

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Expert Opinions                                         

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global, regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • to provide both individuals and organizations a strong financial foothold in the marketInvestment opportunitiesExpertly devised analyst overview along with
  •  
  1. Global Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  2. Global Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  3. Global Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Global Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  5. Global Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  6. Global Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  7. Global Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  8. Global Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  9. Global PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  10. Global TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  11. Global CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  12. Global Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  13. Global ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  14. Global CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  15. Global Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  16. Global Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  17. Global Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  18. Global Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  19. Global HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  20. Global Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  23. North America Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  24. North America Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  25. North America Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  26. North America Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  28. North America Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  31. North America CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  32. North America Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  33. North America ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  34. North America CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  35. North America Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  36. North America Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  37. North America Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  38. North America Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  39. North America HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  40. North America Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  41. United States Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  42. Canada Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  43. United States Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  44. Canada Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  45. United States Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  46. Canada Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  47. United States Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  48. Canada Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  49. Europe Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  50. Europe Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  51. Europe Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  52. Europe Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  53. Europe Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  54. Europe Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  55. Europe Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  56. Europe Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  57. Europe PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  58. Europe TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  59. Europe CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  60. Europe Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  61. Europe ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  62. Europe CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  63. Europe Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  64. Europe Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  65. Europe Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  66. Europe Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  67. Europe HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  68. Europe Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  69. U.K. Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  70. Germany Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  71. France Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  72. Italy Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  73. Spain Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  74. U.K. Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  75. Germany Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  76. France Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  77. Italy Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  78. Spain Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  79. U.K. Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  80. Germany Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  81. France Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  82. Italy Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  83. Spain Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  84. U.K. Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  85. Germany Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  86. France Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  87. Italy Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  88. Spain Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  89. Asia-Pacific Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  90. Asia-Pacific Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  91. Asia-Pacific Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  92. Asia-Pacific Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  93. Asia-Pacific Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  94. Asia-Pacific Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  95. Asia-Pacific Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  96. Asia-Pacific Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  97. Asia-Pacific PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  98. Asia-Pacific TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  99. Asia-Pacific CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  100. Asia-Pacific Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  101. Asia-Pacific ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  102. Asia-Pacific CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  103. Asia-Pacific Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  104. Asia-Pacific Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  105. Asia-Pacific Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  106. Asia-Pacific Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  107. Asia-Pacific HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  108. Asia-Pacific Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  109. China Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  110. India Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  111. Japan Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  112. South Korea Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  113. China Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  114. India Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  115. Japan Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  116. South Korea Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  117. China Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  118. India Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  119. Japan Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  120. South Korea Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  121. China Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  122. India Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  123. Japan Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  124. South Korea Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  125. Latin America Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  126. Latin America Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  127. Latin America Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  128. Latin America Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  129. Latin America Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  130. Latin America Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  131. Latin America Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  132. Latin America Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  133. Latin America PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  134. Latin America TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  135. Latin America CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  136. Latin America Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  137. Latin America ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  138. Latin America CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  139. Latin America Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  140. Latin America Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  141. Latin America Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  142. Latin America Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  143. Latin America HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  144. Latin America Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  145. Brazil Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  146. Argentina Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  147. Mexico Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  148. Brazil Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  149. Argentina Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  150. Mexico Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  151. Brazil Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  152. Argentina Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  153. Mexico Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  154. Brazil Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  155. Argentina Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  156. Mexico Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  157. Middle East & Africa Therapeutic Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  158. Middle East & Africa Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  159. Middle East & Africa Autoimmune Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  160. Middle East & Africa Cancer Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  161. Middle East & Africa Neurological Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  162. Middle East & Africa Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  163. Middle East & Africa Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  164. Middle East & Africa Multikine Market, By Region, From 2021 to 2026 (USD Billion)
  165. Middle East & Africa PR1 Peptide Market, By Region, From 2021 to 2026 (USD Billion)
  166. Middle East & Africa TroVax Market, By Region, From 2021 to 2026 (USD Billion)
  167. Middle East & Africa CYT004-MelQbG10 Market, By Region, From 2021 to 2026 (USD Billion)
  168. Middle East & Africa Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  169. Middle East & Africa ACC- 001 Market, By Region, From 2021 to 2026 (USD Billion)
  170. Middle East & Africa CAD 106 Market, By Region, From 2021 to 2026 (USD Billion)
  171. Middle East & Africa Parkinson's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  172. Middle East & Africa Alzheimer's Vaccine Market, By Region, From 2021 to 2026 (USD Billion)
  173. Middle East & Africa Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  174. Middle East & Africa Hepatitis C Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  175. Middle East & Africa HIV/AIDS Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  176. Middle East & Africa Other Infectious Disease Vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  177. Middle East Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  178. Africa Therapeutic Vaccines Market, By Disease Type, From 2021 to 2026 (USD Billion)
  179. Middle East Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  180. Africa Cancer Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  181. Middle East Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  182. Africa Neurological Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  183. Middle East Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)
  184. Africa Infectious Disease Vaccines Market, By Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample